FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Amedica Secures $20MM Debt Facility From Hercules Technology Growth Capital

July 02, 2014, 07:26 AM
Filed Under: Medical

Amedica Corporation, a biomaterial company focused on using its Silicon Nitride technology platform to develop, manufacture and sell a broad range of medical devices, announced that it has secured up to $26.0 million in additional funding consisting of a $20.0 million debt financing with Hercules Technology Growth Capital, Inc. and a private placement to MG Partners II Ltd., an affiliate of Magna ("Magna"), of 6% Senior Convertible Notes in an aggregate principal amount of up to $6 million.

Approximately $15.2 million of the proceeds from the financing will be used to retire Amedica's senior secured credit facility with General Electric Capital Corporation and the balance will be used to further the commercialization and development of Amedica's Silicon Nitride spinal fusion products and its product candidates for use in total hip and knee joint replacements, and for general corporate purposes.

Jay Moyes, Chief Financial Officer for Amedica indicated that, "the repayment of the GE Credit Facility will eliminate approximately $3.6 million of remaining scheduled principal payments in 2014, which would have otherwise been due under the GE Credit Facility. This will enable the company to now expend those resources on the commercialization of its products."

"This is a significant milestone for the company," stated Eric Olson, President and Chief Executive Officer of Amedica. "Refinancing the GE Credit Facility and securing the additional working capital now puts us in a stronger financial position to further our company objectives. We are pleased to have the support of such reputable financial institutions as Hercules Technology Growth Capital and Magna in maximizing the potential of our silicon nitride biomaterial."

General terms of the Hercules loan agreement include interest-only payments for 12 months until July 1, 2015, with the possibility of extending the interest-only period to eighteen months. Following the interest-only period, Amedica will repay the loan in equal monthly payments of principal and interest through the scheduled maturity date on January 1, 2018. The loan is secured by a perfected first position lien on all of Amedica's assets, including intellectual property. In addition, the Company has issued Hercules a warrant to purchase up to 516,129 shares of Common Stock at an exercise price of $4.65 per share.

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.